Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2025

Core Insights - Nxera Pharma's President & CEO, Chris Cargill, will participate in a 'Fireside Chat' at the Jefferies London Healthcare Conference on 17 November 2025, discussing the company's strategy, recent progress, and upcoming milestones [1] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines for patients with unmet needs in Japan and globally [4] - The company has established a new-generation commercial business in Japan, aiming to develop and commercialize innovative medicines for a large and growing market in the APAC region [4] Pipeline and Innovation - Nxera Pharma is advancing a pipeline of over 30 active programs, utilizing its unique NxWave™ discovery platform, targeting major unmet needs in obesity, metabolic disorders, neurology/neuropsychiatry, and immunology/inflammation [5] - The pipeline includes potentially first- and best-in-class candidates, indicating a strong focus on innovation and addressing critical health issues [5] Workforce and Global Presence - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, highlighting its international footprint [6]